– USA, PA – AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a biotechnology company with operations in the USA and China, today announced the appointment of Jiawen Kang to its board of directors effective August 2, 2022.
Concurrently, the Company also announced the appointment of Yuyang Cui as Co-Chairman of the Board and Co-CEO.
Jiawen Kang will also join the Audit Committee and the Nominating Committee.
About Yuyang Cui
As Co-CEO, Yuyang Cui will be primarily responsible for searching and presenting potential business opportunities to the Company and the Board as well as the capital markets strategy and related activities for AnPac Bio.
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of March 31, 2022. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA, bio-chemical, immunological, and genomics tests. According to a report by Frost & Sullivan, AnPac Bio ranked first globally in multi-cancer screening and detection test sample volume. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.
For more information : https://www.anpacbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.